Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Cancer Institute CRADA

Executive Summary

NCI seeks pharmaceutical company partner to develop LMB-7 recombinant immunotoxin for certain cancers. In an April 14 Federal Register notice announcing the availability of the Cooperative Research and Development Agreement, NCI states that LMB-7 "has been shown to cause the complete regression of human cancers growing in immunodeficient mice." Questions concerning the LMB-7 CRADA should be directed to Ira Pastan, MD, NCI Division of Cancer Biology Diagnosis and Centers, (301) 496-4797.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022469

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel